There are 2789 resources available
478P - TA-ness classification discriminates RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) who may benefit from antiEGFR treatment
Presenter: Cristina Santos
Session: ePoster Display
697P - Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)
Presenter: Carolina Alves Costa Silva
Session: ePoster Display
698P - Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
Presenter: Jonathan Rosenberg
Session: ePoster Display
699P - Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)
Presenter: Jonathan Rosenberg
Session: ePoster Display
700P - Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC)
Presenter: Yohann Loriot
Session: ePoster Display
1340P - The characteristics of the intestinal flora of advanced non-small cell lung cancer in China and its role in chemotherapy based on metagenomics
Presenter: Xiangjun Liu
Session: ePoster Display
Resources:
Abstract
1341P - NRAS mutated non-small cell lung cancer (NSCLC) patients: Characteristics and outcomes
Presenter: Agathe Dehem
Session: ePoster Display
1342P - Genetic mutations in PIK3CA predict liver metastases in patients with lung adenocarcinoma
Presenter: Jun Zhao
Session: ePoster Display
1343P - Understanding patient and caregiver perceptions of quality of life (QoL) impacts in lung cancer through social listening
Presenter: Michele Montrone
Session: ePoster Display